仙乐健康 (300791.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.7x

Market Cap

CNY 5.23B

MomentumView details →

1D Return

+2.66%

YTD Return

−31.40%

RSI (14)

56.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.7x

Market Cap

CNY 5.23B

RSI (14)

56.6

MomentumView details →

1D Return

+2.66%

YTD Return

−31.40%

ProfitabilityView details →

Gross Margin

30.43%

Net Margin

2.73%

EBITDA Margin

5.84%

ROE (TTM)

3.98%

ROA (TTM)

2.06%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

+2.33%

EPS YoY

−64.45%

FCF YoY

−87.43%

Revenue CAGR 3Y

+19.35%

EPS CAGR 3Y

−27.64%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

1.85x

Quick Ratio

1.41x

Div Yield

0.73%

Div Rate

CNY 0.13

Div Growth 1Y

−74.00%

Financials snapshotView financials →

Revenue (TTM)

4.31B

Net Income (TTM)

117.80M

Op. CF (TTM)

491.66M

Next earningsOct 22, 2026 →

Latest newsMore news →

Sirio Pharma announced its first-half 2026 results: revenue of 2.052 billion yuan, up 0.51% year-on-year; net profit attributable to shareholders of 153 million yuan, down 5.09% year-on-year.8d ago

Similar companies

华昌达300278.SZ 满坤科技301132.SZ 西麦食品002956.SZ 新铝时代301613.SZ 百川股份002455.SZ 优博讯300531.SZ Find similar companies →

Latest newsMore news →

Sirio Pharma announced its first-half 2026 results: revenue of 2.052 billion yuan, up 0.51% year-on-year; net profit attributable to shareholders of 153 million yuan, down 5.09% year-on-year.8d ago